prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy
Published 8 months ago • 97 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
4:22
the role of mrd in aml
-
1:49
bringing precision medicine and mrd into clinical strategies
-
3:10
novel aml treament approaches
-
3:11
assessment of mrd in aml
-
1:37
mrd in myeloma
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
4:36
haemonetics
-
52:51
conducting a risk assessment for money laundering
-
27:32
chapter 7: treatment of specific hemorrhages
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
3:16
developing patient-specific mrd markers for predicting and preventing mds relapse post-sct
-
2:15
improving the specificity of molecular mrd detection
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:45
role for mrd assessment in al amyloidosis?
-
1:33
tourmaline-mm3: undetectable mrd as an endpoint for maintenance therapy
-
1:04
the future of mds management
-
4:48
an insight into the management of cytopenias in mf
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
4:40
management of r/r myeloma and mrd assessment
-
1:21
intensive therapy of older aml
-
5:36
venetoclax and azacitidine in mds patients
-
0:38
optimal time for allo-hsct in aml